Mesenchymal stem cell-mediated effects of tumor support or suppression

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 30015-30033

  Rhee, Ki Jong ^a   Lee, Jong In ^b   Eom, Young Woo ^b  

^a Yonsei University Wonju   (South Korea)

^b Yonsei University Wonju College of Medicine   (South Korea)

Author keywords

Delivery vehicles; Homing; Mesenchymal stem cells; Tumor microenvironment

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN 4; BONE MORPHOGENETIC PROTEIN 6; BRAIN DERIVED NEUROTROPHIC FACTOR; EPIDERMAL GROWTH FACTOR; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; FIBROBLAST GROWTH FACTOR 2; GAMMA INTERFERON; GRANULOCYTE CHEMOTACTIC PROTEIN 2; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RANTES; SCATTER FACTOR; SOMATOMEDIN C; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; WNT PROTEIN; X LINKED INHIBITOR OF APOPTOSIS; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER CELL LINE; CANCER INHIBITION; CANCER STEM CELL; CELL CYCLE CHECKPOINT; CELL CYCLE REGULATION; CELL INTERACTION; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GENE EXPRESSION REGULATION; GROWTH INHIBITION; HUMAN; IMMUNOREGULATION; INFLAMMATORY INFILTRATE; MESENCHYMAL STEM CELL TRANSPLANTATION; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; REGENERATIVE MEDICINE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY; CARCINOGENESIS; CELL PROLIFERATION; MESENCHYMAL STROMA CELL; METABOLISM; NEOPLASMS; PATHOLOGY;

CARCINOGENESIS; CELL PROLIFERATION; HUMANS; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

EID: 84949953762     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226215     Document Type: Article

References (210)

1. Dominici, M.; le Blanc, K.; Mueller, I.; Slaper-Cortenbach, I.; Marini, F.; Krause, D.; Deans, R.; Keating, A.; Prockop, D.; Horwitz, E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006, 8, 315-317. [CrossRef] [PubMed]
2. Campagnoli, C.; Roberts, I. A.; Kumar, S.; Bennett, P. R.; Bellantuono, I.; Fisk, N. M. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 2001, 98, 2396-2402. [CrossRef] [PubMed]
3. De Ugarte, D. A.; Morizono, K.; Elbarbary, A.; Alfonso, Z.; Zuk, P. A.; Zhu, M.; Dragoo, J. L.; Ashjian, P.; Thomas, B.; Benhaim, P.; et al. Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs 2003, 174, 101-109. [CrossRef] [PubMed]
4. Erices, A.; Conget, P.; Minguell, J. J. Mesenchymal progenitor cells in human umbilical cord blood. Br. J. Haematol. 2000, 109, 235-242. [CrossRef] [PubMed]
5. Jiang, Y.; Vaessen, B.; Lenvik, T.; Blackstad, M.; Reyes, M.; Verfaillie, C. M. Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp. Hematol. 2002, 30, 896-904. [CrossRef]
6. Young, H. E.; Steele, T. A.; Bray, R. A.; Hudson, J.; Floyd, J. A.; Hawkins, K.; Thomas, K.; Austin, T.; Edwards, C.; Cuzzourt, J.; et al. Human reserve pluripotent mesenchymal stem cells are present in the connective tissues of skeletal muscle and dermis derived from fetal, adult, and geriatric donors. Anat. Rec. 2001, 264, 51-62. [CrossRef] [PubMed]
7. Zvaifler, N. J.; Marinova-Mutafchieva, L.; Adams, G.; Edwards, C. J.; Moss, J.; Burger, J. A.; Maini, R. N. Mesenchymal precursor cells in the blood of normal individuals. Arthritis Res. 2000, 2, 477-488. [CrossRef] [PubMed]
8. Yoo, K. H.; Jang, I. K.; Lee, M. W.; Kim, H. E.; Yang, M. S.; Eom, Y.; Lee, J. E.; Kim, Y. J.; Yang, S. K.; Jung, H. L.; et al. Comparison of immunomodulatory properties of mesenchymal stem cells derived from adult human tissues. Cell. Immunol. 2009, 259, 150-156. [CrossRef] [PubMed]
9. Pendleton, C.; Li, Q.; Chesler, D. A.; Yuan, K.; Guerrero-Cazares, H.; Quinones-Hinojosa, A. Mesenchymal stem cells derived from adipose tissue vs bone marrow: In vitro comparison of their tropism towards gliomas. PLoS ONE 2013, 8. [CrossRef] [PubMed]
10. Kidd, S.; Spaeth, E.; Watson, K.; Burks, J.; Lu, H.; Klopp, A.; Andreeff, M.; Marini, F. C. Origins of the tumor microenvironment: Quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS ONE 2012, 7. [CrossRef] [PubMed]
11. Jansen, B. J.; Gilissen, C.; Roelofs, H.; Schaap-Oziemlak, A.; Veltman, J. A.; Raymakers, R. A.; Jansen, J. H.; Kogler, G.; Figdor, C. G.; Torensma, R.; et al. Functional differences between mesenchymal stem cell populations are reflected by their transcriptome. Stem Cells Dev. 2010, 19, 481-490. [CrossRef] [PubMed]
12. Mosna, F.; Sensebe, L.; Krampera, M. Human bone marrow and adipose tissue mesenchymal stem cells: A user's guide. Stem Cells Dev. 2010, 19, 1449-1470. [CrossRef] [PubMed]
13. Uccelli, A.; Moretta, L.; Pistoia, V. Mesenchymal stem cells in health and disease. Nat. Rev. Immunol. 2008, 8, 726-736. [CrossRef] [PubMed]
14. Liu, Z. J.; Zhuge, Y.; Velazquez, O. C. Trafficking and differentiation of mesenchymal stem cells. J. Cell. Biochem. 2009, 106, 984-991. [CrossRef] [PubMed]
15. Haynesworth, S. E.; Goshima, J.; Goldberg, V. M.; Caplan, A. I. Characterization of cells with osteogenic potential from human marrow. Bone 1992, 13, 81-88. [CrossRef]
16. Pittenger, M. F.; Mackay, A. M.; Beck, S. C.; Jaiswal, R. K.; Douglas, R.; Mosca, J. D.; Moorman, M. A.; Simonetti, D. W.; Craig, S.; Marshak, D. R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284, 143-147. [CrossRef] [PubMed]
17. Prockop, D. J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276, 71-74. [CrossRef] [PubMed]
18. Dai, L. J.; Li, H. Y.; Guan, L. X.; Ritchie, G.; Zhou, J. X. The therapeutic potential of bone marrow-derived mesenchymal stem cells on hepatic cirrhosis. Stem Cell Res. 2009, 2, 16-25. [CrossRef] [PubMed]
19. Sharma, R. R.; Pollock, K.; Hubel, A.; McKenna, D. Mesenchymal stem or stromal cells: A review of clinical applications and manufacturing practices. Transfusion 2014, 54, 1418-1437. [CrossRef] [PubMed]
20. Augello, A.; Tasso, R.; Negrini, S. M.; Amateis, A.; Indiveri, F.; Cancedda, R.; Pennesi, G. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 2005, 35, 1482-1490. [CrossRef] [PubMed]
21. Haddad, R.; Saldanha-Araujo, F. Mechanisms of T-cell immunosuppression by mesenchymal stromal cells: What do we know so far? Biomed. Res. Int. 2014, 2014. [CrossRef] [PubMed]
22. Najar, M.; Raicevic, G.; Fayyad-Kazan, H.; de Bruyn, C.; Bron, D.; Toungouz, M.; Lagneaux, L. Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: The expression and impact of inflammatory priming. Stem Cell Rev. 2012, 8, 1188-1198. [CrossRef] [PubMed]
23. Kupcova-Skalnikova, H. Proteomic techniques for characterisation of mesenchymal stem cell secretome. Biochimie 2013, 95, 2196-2211. [CrossRef] [PubMed]
24. Sakaida, I.; Terai, S.; Yamamoto, N.; Aoyama, K.; Ishikawa, T.; Nishina, H.; Okita, K. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004, 40, 1304-1311. [CrossRef] [PubMed]
25. Wang, L.; Wang, X.; Wang, L.; Chiu, J. D.; van de Ven, G.; Gaarde, W. A.; Deleve, L. D. Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells. Gastroenterology 2012, 143, 1555-1563. [CrossRef] [PubMed]
26. Kim, S. U.; Oh, H. J.; Wanless, I. R.; Lee, S.; Han, K. H.; Park, Y. N. The Laennec staging system for histological sub-classification of cirrhosis is useful for stratification of prognosis in patients with liver cirrhosis. J. Hepatol. 2012, 57, 556-563. [CrossRef] [PubMed]
27. Wu, Y.; Zhao, R. C.; Tredget, E. E. Concise review: Bone marrow-derived stem/progenitor cells in cutaneous repair and regeneration. Stem Cells 2010, 28, 905-915. [PubMed]
28. Crisostomo, P. R.; Wang, Y.; Markel, T. A.; Wang, M.; Lahm, T.; Meldrum, D. R. Human mesenchymal stem cells stimulated by TNF-α, LPS, or hypoxia produce growth factors by an NFkB-but not JNK-dependent mechanism. Am. J. Physiol. Cell Physiol. 2008, 294, C675-C682. [CrossRef] [PubMed]
29. Caplan, A. I.; Dennis, J. E. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 2006, 98, 1076-1084. [CrossRef] [PubMed]
30. Beckermann, B. M.; Kallifatidis, G.; Groth, A.; Frommhold, D.; Apel, A.; Mattern, J.; Salnikov, A. V.; Moldenhauer, G.; Wagner, W.; Diehlmann, A.; et al. VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br. J. Cancer 2008, 99, 622-631. [CrossRef] [PubMed]
31. Block, G. J.; Ohkouchi, S.; Fung, F.; Frenkel, J.; Gregory, C.; Pochampally, R.; DiMattia, G.; Sullivan, D. E.; Prockop, D. J. Multipotent stromal cells are activated to reduce apoptosis in part by upregulation and secretion of stanniocalcin-1. Stem Cells 2009, 27, 670-681. [CrossRef] [PubMed]
32. Dvorak, H. F. Tumors: Wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315, 1650-1659. [PubMed]
33. Kaneko, Y.; Tajiri, N.; Staples, M.; Reyes, S.; Lozano, D.; Sanberg, P. R.; Freeman, T. B.; van Loveren, H.; Kim, S. U.; Borlongan, C. V. Bone marrow-derived stem cell therapy for metastatic brain cancers. Cell Transplant. 2015, 24, 625-630. [CrossRef] [PubMed]
34. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646-674. [CrossRef] [PubMed]
35. Klopp, A. H.; Gupta, A.; Spaeth, E.; Andreeff, M.; Marini, F., 3rd. Concise review: Dissecting a discrepancy in the literature: Do mesenchymal stem cells support or suppress tumor growth? Stem Cells 2011, 29, 11-19. [CrossRef] [PubMed]
36. Zhang, Y.; Daquinag, A.; Traktuev, D. O.; Amaya-Manzanares, F.; Simmons, P. J.; March, K. L.; Pasqualini, R.; Arap, W.; Kolonin, M. G. White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res. 2009, 69, 5259-5266. [CrossRef] [PubMed]
37. Jotzu, C.; Alt, E.; Welte, G.; Li, J.; Hennessy, B. T.; Devarajan, E.; Krishnappa, S.; Pinilla, S.; Droll, L.; Song, Y. H. Adipose tissue derived stem cells differentiate into carcinoma-associated fibroblast-like cells under the influence of tumor derived factors. Cell. Oncol. 2011, 34, 55-67. [CrossRef] [PubMed]
38. Pinilla, S.; Alt, E.; Abdul Khalek, F. J.; Jotzu, C.; Muehlberg, F.; Beckmann, C.; Song, Y. H. Tissue resident stem cells produce CCL5 under the influence of cancer cells and thereby promote breast cancer cell invasion. Cancer Lett. 2009, 284, 80-85. [CrossRef] [PubMed]
39. Krohn, A.; Song, Y. H.; Muehlberg, F.; Droll, L.; Beckmann, C.; Alt, E. CXCR4 receptor positive spheroid forming cells are responsible for tumor invasion in vitro. Cancer Lett. 2009, 280, 65-71. [CrossRef] [PubMed]
40. Khakoo, A. Y.; Pati, S.; Anderson, S. A.; Reid, W.; Elshal, M. F.; Rovira, I. I.; Nguyen, A. T.; Malide, D.; Combs, C. A.; Hall, G.; et al. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med. 2006, 203, 1235-1247. [CrossRef] [PubMed]
41. Qiao, L.; Xu, Z.; Zhao, T.; Zhao, Z.; Shi, M.; Zhao, R. C.; Ye, L.; Zhang, X. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res. 2008, 18, 500-507. [CrossRef] [PubMed]
42. Qiao, L.; Xu, Z. L.; Zhao, T. J.; Ye, L. H.; Zhang, X. D. Dkk-1 secreted by mesenchymal stem cells inhibits growth of breast cancer cells via depression of Wnt signalling. Cancer Lett. 2008, 269, 67-77. [CrossRef] [PubMed]
43. Zhu, Y.; Sun, Z.; Han, Q.; Liao, L.; Wang, J.; Bian, C.; Li, J.; Yan, X.; Liu, Y.; Shao, C.; et al. Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia 2009, 23, 925-933. [CrossRef] [PubMed]
44. Cousin, B.; Ravet, E.; Poglio, S.; de Toni, F.; Bertuzzi, M.; Lulka, H.; Touil, I.; Andre, M.; Grolleau, J. L.; Peron, J. M.; et al. Adult stromal cells derived from human adipose tissue provoke pancreatic cancer cell death both in vitro and in vivo. PLoS ONE 2009, 4. [CrossRef] [PubMed]
45. Dasari, V. R.; Kaur, K.; Velpula, K. K.; Gujrati, M.; Fassett, D.; Klopfenstein, J. D.; Dinh, D. H.; Rao, J. S. Upregulation of PTEN in glioma cells by cord blood mesenchymal stem cells inhibits migration via downregulation of the PI3K/Akt pathway. PLoS ONE 2010, 5. [CrossRef] [PubMed]
46. Dasari, V. R.; Velpula, K. K.; Kaur, K.; Fassett, D.; Klopfenstein, J. D.; Dinh, D. H.; Gujrati, M.; Rao, J. S. Cord blood stem cell-mediated induction of apoptosis in glioma downregulates X-linked inhibitor of apoptosis protein (XIAP). PLoS ONE 2010, 5. [CrossRef] [PubMed]
47. Otsu, K.; Das, S.; Houser, S. D.; Quadri, S. K.; Bhattacharya, S.; Bhattacharya, J. Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 2009, 113, 4197-4205. [CrossRef] [PubMed]
48. Li, H.; Fan, X.; Houghton, J. Tumor microenvironment: The role of the tumor stroma in cancer. J. Cell. Biochem. 2007, 101, 805-815. [CrossRef] [PubMed]
49. Bissell, M. J.; Radisky, D. Putting tumours in context. Nat. Rev. Cancer 2001, 1, 46-54. [CrossRef] [PubMed]
50. Studeny, M.; Marini, F. C.; Dembinski, J. L.; Zompetta, C.; Cabreira-Hansen, M.; Bekele, B. N.; Champlin, R. E.; Andreeff, M. Mesenchymal stem cells: Potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 2004, 96, 1593-1603. [CrossRef] [PubMed]
51. Kidd, S.; Spaeth, E.; Dembinski, J. L.; Dietrich, M.; Watson, K.; Klopp, A.; Battula, V. L.; Weil, M.; Andreeff, M.; Marini, F. C. Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging. Stem Cells 2009, 27, 2614-2623. [CrossRef] [PubMed]
52. Karnoub, A. E.; Dash, A. B.; Vo, A. P.; Sullivan, A.; Brooks, M. W.; Bell, G. W.; Richardson, A. L.; Polyak, K.; Tubo, R.; Weinberg, R. A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007, 449, 557-563. [CrossRef] [PubMed]
53. Xu, W. T.; Bian, Z. Y.; Fan, Q. M.; Li, G.; Tang, T. T. Human mesenchymal stem cells (HMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. Cancer Lett. 2009, 281, 32-41. [CrossRef] [PubMed]
54. Zhu, W.; Xu, W.; Jiang, R.; Qian, H.; Chen, M.; Hu, J.; Cao, W.; Han, C.; Chen, Y. Mesenchymal stem cells derived from bone marrow favor tumor cell growth in vivo. Exp. Mol. Pathol. 2006, 80, 267-274. [CrossRef] [PubMed]
55. Spaeth, E. L.; Dembinski, J. L.; Sasser, A. K.; Watson, K.; Klopp, A.; Hall, B.; Andreeff, M.; Marini, F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS ONE 2009, 4. [CrossRef] [PubMed]
56. Djouad, F.; Plence, P.; Bony, C.; Tropel, P.; Apparailly, F.; Sany, J.; Noel, D.; Jorgensen, C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 2003, 102, 3837-3844. [CrossRef] [PubMed]
57. Mueller, M. M.; Fusenig, N. E. Friends or foes-Bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer 2004, 4, 839-849. [CrossRef] [PubMed]
58. Sappino, A. P.; Skalli, O.; Jackson, B.; Schurch, W.; Gabbiani, G. Smooth-muscle differentiation in stromal cells of malignant and non-malignant breast tissues. Int. J. Cancer 1988, 41, 707-712. [CrossRef] [PubMed]
59. Orimo, A.; Gupta, P. B.; Sgroi, D. C.; Arenzana-Seisdedos, F.; Delaunay, T.; Naeem, R.; Carey, V. J.; Richardson, A. L.; Weinberg, R. A. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121, 335-348. [CrossRef] [PubMed]
60. Muller, A.; Homey, B.; Soto, H.; Ge, N.; Catron, D.; Buchanan, M. E.; McClanahan, T.; Murphy, E.; Yuan, W.; Wagner, S. N.; et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001, 410, 50-56. [CrossRef] [PubMed]
61. Mishra, P. J.; Mishra, P. J.; Humeniuk, R.; Medina, D. J.; Alexe, G.; Mesirov, J. P.; Ganesan, S.; Glod, J. W.; Banerjee, D. Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. Cancer Res. 2008, 68, 4331-4339. [CrossRef] [PubMed]
62. Quante, M.; Tu, S. P.; Tomita, H.; Gonda, T.; Wang, S. S.; Takashi, S.; Baik, G. H.; Shibata, W.; Diprete, B.; Betz, K. S.; et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 2011, 19, 257-272. [CrossRef] [PubMed]
63. Wang, D.; Park, J. S.; Chu, J. S.; Krakowski, A.; Luo, K.; Chen, D. J.; Li, S. Proteomic profiling of bone marrow mesenchymal stem cells upon transforming growth factor β1 stimulation. J. Biol. Chem. 2004, 279, 43725-43734. [CrossRef] [PubMed]
64. Robbins, P. F.; Lu, Y. C.; El-Gamil, M.; Li, Y. F.; Gross, C.; Gartner, J.; Lin, J. C.; Teer, J. K.; Cliften, P.; Tycksen, E.; et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 2013, 19, 747-752. [CrossRef] [PubMed]
65. Matsushita, H.; Vesely, M. D.; Koboldt, D. C.; Rickert, C. G.; Uppaluri, R.; Magrini, V. J.; Arthur, C. D.; White, J. M.; Chen, Y. S.; Shea, L. K.; et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012, 482, 400-404. [CrossRef] [PubMed]
66. Mantovani, A.; Schioppa, T.; Porta, C.; Allavena, P.; Sica, A. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006, 25, 315-322. [CrossRef] [PubMed]
67. Sica, A.; Schioppa, T.; Mantovani, A.; Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. Eur. J. Cancer 2006, 42, 717-727. [CrossRef] [PubMed]
68. Condeelis, J.; Pollard, J. W. Macrophages: Obligate partners for tumor cell migration, invasion, and metastasis. Cell 2006, 124, 263-266. [CrossRef] [PubMed]
69. Lamagna, C.; Aurrand-Lions, M.; Imhof, B. A. Dual role of macrophages in tumor growth and angiogenesis. J. Leukoc. Biol. 2006, 80, 705-713. [CrossRef] [PubMed]
70. Coffelt, S. B.; Hughes, R.; Lewis, C. E. Tumor-associated macrophages: Effectors of angiogenesis and tumor progression. Biochim. Biophys. Acta 2009, 1796, 11-18. [CrossRef] [PubMed]
71. Siveen, K. S.; Kuttan, G. Role of macrophages in tumour progression. Immunol. Lett. 2009, 123, 97-102. [CrossRef] [PubMed]
72. Lewis, C. E.; Pollard, J. W. Distinct role of macrophages in different tumor microenvironments. Cancer Res. 2006, 66, 605-612. [CrossRef] [PubMed]
73. Mantovani, A.; Sica, A.; Allavena, P.; Garlanda, C.; Locati, M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 2009, 70, 325-330. [CrossRef] [PubMed]
74. Mills, C. D.; Kincaid, K.; Alt, J. M.; Heilman, M. J.; Hill, A. M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J. Immunol. 2000, 164, 6166-6173. [CrossRef] [PubMed]
75. Leek, R. D.; Hunt, N. C.; Landers, R. J.; Lewis, C. E.; Royds, J. A.; Harris, A. L. Macrophage infiltration is associated with VEGF and EGFR expression in breast cancer. J. Pathol. 2000, 190, 430-436. [CrossRef]
76. Zhang, J.; Lu, Y.; Pienta, K. J. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J. Natl. Cancer Inst. 2010, 102, 522-528. [CrossRef] [PubMed]
77. Kosaka, T.; Kuwabara, M.; Endo, A.; Tamaguchi, H.; Koide, F. Expression of arginase by mouse myeloid leukemic cell differentiation in vitro induced with tumor necrosis factor. J. Vet. Med. Sci. 1991, 53, 53-57. [CrossRef] [PubMed]
78. Tsung, K.; Dolan, J. P.; Tsung, Y. L.; Norton, J. A. Macrophages as effector cells in interleukin 12-induced T cell-dependent tumor rejection. Cancer Res. 2002, 62, 5069-5075. [PubMed]
79. Brigati, C.; Noonan, D. M.; Albini, A.; Benelli, R. Tumors and inflammatory infiltrates: Friends or foes? Clin. Exp. Metastasis 2002, 19, 247-258. [CrossRef] [PubMed]
80. Bingle, L.; Brown, N. J.; Lewis, C. E. The role of tumour-associated macrophages in tumour progression: Implications for new anticancer therapies. J. Pathol. 2002, 196, 254-265. [CrossRef] [PubMed]
81. Leek, R. D.; Harris, A. L. Tumor-associated macrophages in breast cancer. J. Mammary Gland Biol. Neoplasia 2002, 7, 177-189. [CrossRef] [PubMed]
82. Van der Bij, G. J.; Oosterling, S. J.; Meijer, S.; Beelen, R. H.; van Egmond, M. The role of macrophages in tumor development. Cell. Oncol. 2005, 27, 203-213. [PubMed]
83. Li, H. J.; Reinhardt, F.; Herschman, H. R.; Weinberg, R. A. Cancer-stimulated mesenchymal stem cells create a carcinoma stem cell niche via prostaglandin E2 signaling. Cancer Discov. 2012, 2, 840-855. [CrossRef] [PubMed]
84. Nakao, S.; Kuwano, T.; Tsutsumi-Miyahara, C.; Ueda, S.; Kimura, Y. N.; Hamano, S.; Sonoda, K. H.; Saijo, Y.; Nukiwa, T.; Strieter, R. M.; et al. Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1β-induced neovascularization and tumor growth. J. Clin. Investig. 2005, 115, 2979-2991. [CrossRef] [PubMed]
85. Torisu, H.; Ono, M.; Kiryu, H.; Furue, M.; Ohmoto, Y.; Nakayama, J.; Nishioka, Y.; Sone, S.; Kuwano, M. Macrophage infiltration correlates with tumor stage and angiogenesis in human malignant melanoma: Possible involvement of TNFα and IL-1α. Int. J. Cancer 2000, 85, 182-188. [CrossRef]
86. Voswinkel, J.; Francois, S.; Simon, J. M.; Benderitter, M.; Gorin, N. C.; Mohty, M.; Fouillard, L.; Chapel, A. Use of mesenchymal stem cells (MSC) in chronic inflammatory fistulizing and fibrotic diseases: A comprehensive review. Clin. Rev. Allergy Immunol. 2013, 45, 180-192. [CrossRef] [PubMed]
87. Volarevic, V.; al-Qahtani, A.; Arsenijevic, N.; Pajovic, S.; Lukic, M. L. Interleukin-1 receptor antagonist (IL-1Ra) and IL-1Ra producing mesenchymal stem cells as modulators of diabetogenesis. Autoimmunity 2010, 43, 255-263. [CrossRef] [PubMed]
88. Parekkadan, B.; van Poll, D.; Suganuma, K.; Carter, E. A.; Berthiaume, F.; Tilles, A. W.; Yarmush, M. L. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE 2007, 2. [CrossRef] [PubMed]
89. Nemeth, K.; Leelahavanichkul, A.; Yuen, P. S.; Mayer, B.; Parmelee, A.; Doi, K.; Robey, P. G.; Leelahavanichkul, K.; Koller, B. H.; Brown, J. M.; et al. Bone marrow stromal cells attenuate sepsis via prostaglandin E2-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat. Med. 2009, 15, 42-49. [CrossRef] [PubMed]
90. Spaggiari, G. M.; Abdelrazik, H.; Becchetti, F.; Moretta, L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: Central role of MSC-derived prostaglandin E2. Blood 2009, 113, 6576-6583. [CrossRef] [PubMed]
91. Djouad, F.; Charbonnier, L. M.; Bouffi, C.; Louis-Plence, P.; Bony, C.; Apparailly, F.; Cantos, C.; Jorgensen, C.; Noel, D. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007, 25, 2025-2032. [CrossRef] [PubMed]
92. Jiang, X. X.; Zhang, Y.; Liu, B.; Zhang, S. X.; Wu, Y.; Yu, X. D.; Mao, N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105, 4120-4126. [CrossRef] [PubMed]
93. Ren, G.; Su, J.; Zhang, L.; Zhao, X.; Ling, W.; L'Huillie, A.; Zhang, J.; Lu, Y.; Roberts, A. I.; Ji, W.; et al. Species variation in the mechanisms of mesenchymal stem cell-mediated immunosuppression. Stem Cells 2009, 27, 1954-1962. [CrossRef] [PubMed]
94. Sato, K.; Ozaki, K.; Oh, I.; Meguro, A.; Hatanaka, K.; Nagai, T.; Muroi, K.; Ozawa, K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109, 228-234. [CrossRef] [PubMed]
95. Green, S. J.; Scheller, L. F.; Marletta, M. A.; Seguin, M. C.; Klotz, F. W.; Slayter, M.; Nelson, B. J.; Nacy, C. A. Nitric oxide: Cytokine-regulation of nitric oxide in host resistance to intracellular pathogens. Immunol. Lett. 1994, 43, 87-94. [CrossRef]
96. Ren, G.; Zhang, L.; Zhao, X.; Xu, G.; Zhang, Y.; Roberts, A. I.; Zhao, R. C.; Shi, Y. Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2008, 2, 141-150. [CrossRef] [PubMed]
97. Mazzoni, A.; Bronte, V.; Visintin, A.; Spitzer, J. H.; Apolloni, E.; Serafini, P.; Zanovello, P.; Segal, D. M. Myeloid suppressor lines inhibit T cell responses by an no-dependent mechanism. J. Immunol. 2002, 168, 689-695. [CrossRef] [PubMed]
98. Rajantie, I.; Ilmonen, M.; Alminaite, A.; Ozerdem, U.; Alitalo, K.; Salven, P. Adult bone marrow-derived cells recruited during angiogenesis comprise precursors for periendothelial vascular mural cells. Blood 2004, 104, 2084-2086. [CrossRef] [PubMed]
99. Bexell, D.; Gunnarsson, S.; Tormin, A.; Darabi, A.; Gisselsson, D.; Roybon, L.; Scheding, S.; Bengzon, J. Bone marrow multipotent mesenchymal stroma cells act as pericyte-like migratory vehicles in experimental gliomas. Mol. Ther. 2009, 17, 183-190. [CrossRef] [PubMed]
100. Kinnaird, T.; Stabile, E.; Burnett, M. S.; Lee, C. W.; Barr, S.; Fuchs, S.; Epstein, S. E. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 2004, 94, 678-685. [CrossRef] [PubMed]
101. Gyongyosi, M.; Posa, A.; Pavo, N.; Hemetsberger, R.; Kvakan, H.; Steiner-Boker, S.; Petrasi, Z.; Manczur, F.; Pavo, I. J.; Edes, I. F.; et al. Differential effect of ischaemic preconditioning on mobilisation and recruitment of haematopoietic and mesenchymal stem cells in porcine myocardial ischaemia-reperfusion. Thromb. Haemost. 2010, 104, 376-384. [CrossRef] [PubMed]
102. Potier, E.; Ferreira, E.; Andriamanalijaona, R.; Pujol, J. P.; Oudina, K.; Logeart-Avramoglou, D.; Petite, H. Hypoxia affects mesenchymal stromal cell osteogenic differentiation and angiogenic factor expression. Bone 2007, 40, 1078-1087. [CrossRef] [PubMed]
103. Zacharek, A.; Chen, J.; Cui, X.; Li, A.; Li, Y.; Roberts, C.; Feng, Y.; Gao, Q.; Chopp, M. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J. Cereb. Blood Flow Metab. 2007, 27, 1684-1691. [CrossRef] [PubMed]
104. Birnbaum, T.; Roider, J.; Schankin, C. J.; Padovan, C. S.; Schichor, C.; Goldbrunner, R.; Straube, A. Malignant gliomas actively recruit bone marrow stromal cells by secreting angiogenic cytokines. J. Neurooncol. 2007, 83, 241-247. [CrossRef] [PubMed]
105. Birnbaum, T.; Hildebrandt, J.; Nuebling, G.; Sostak, P.; Straube, A. Glioblastoma-dependent differentiation and angiogenic potential of human mesenchymal stem cells in vitro. J. Neurooncol. 2011, 105, 57-65. [CrossRef] [PubMed]
106. Au, P.; Tam, J.; Fukumura, D.; Jain, R. K. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood 2008, 111, 4551-4558. [CrossRef] [PubMed]
107. Grunert, S.; Jechlinger, M.; Beug, H. Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat. Rev. Mol. Cell Biol. 2003, 4, 657-665. [CrossRef] [PubMed]
108. Jechlinger, M.; Grunert, S.; Tamir, I. H.; Janda, E.; Ludemann, S.; Waerner, T.; Seither, P.; Weith, A.; Beug, H.; Kraut, N. Expression profiling of epithelial plasticity in tumor progression. Oncogene 2003, 22, 7155-7169. [CrossRef] [PubMed]
109. Cannito, S.; Novo, E.; di Bonzo, L. V.; Busletta, C.; Colombatto, S.; Parola, M. Epithelial-mesenchymal transition: From molecular mechanisms, redox regulation to implications in human health and disease. Antioxid. Redox Signal. 2010, 12, 1383-1430. [CrossRef] [PubMed]
110. Polyak, K.; Weinberg, R. A. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat. Rev. Cancer 2009, 9, 265-273. [CrossRef] [PubMed]
111. Thompson, E. W.; Newgreen, D. F.; Tarin, D. Carcinoma invasion and metastasis: A role for epithelial-mesenchymal transition? Cancer Res. 2005, 65, 5991-5995. [CrossRef] [PubMed]
112. Kong, D.; Wang, Z.; Sarkar, S. H.; Li, Y.; Banerjee, S.; Saliganan, A.; Kim, H. R.; Cher, M. L.; Sarkar, F. H. Platelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cells. Stem Cells 2008, 26, 1425-1435. [CrossRef] [PubMed]
113. Kalluri, R.; Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Investig. 2009, 119, 1420-1428. [CrossRef] [PubMed]
114. Thiery, J. P. Epithelial-mesenchymal transitions in tumour progression. Nat. Rev. Cancer 2002, 2, 442-454. [CrossRef] [PubMed]
115. Tse, J. C.; Kalluri, R. Mechanisms of metastasis: Epithelial-to-mesenchymal transition and contribution of tumor microenvironment. J. Cell. Biochem. 2007, 101, 816-829. [CrossRef] [PubMed]
116. Martin, F. T.; Dwyer, R. M.; Kelly, J.; Khan, S.; Murphy, J. M.; Curran, C.; Miller, N.; Hennessy, E.; Dockery, P.; Barry, F. P.; et al. Potential role of mesenchymal stem cells (MSCs) in the breast tumour microenvironment: Stimulation of epithelial to mesenchymal transition (EMT). Breast Cancer Res. Treat. 2010, 124, 317-326. [CrossRef] [PubMed]
117. Chen, D.; Liu, S.; Ma, H.; Liang, X.; Ma, H.; Yan, X.; Yang, B.; Wei, J.; Liu, X. Paracrine factors from adipose-mesenchymal stem cells enhance metastatic capacity through Wnt signaling pathway in a colon cancer cell co-culture model. Cancer Cell Int. 2015, 15, 42. [PubMed]
118. Strong, A. L.; Ohlstein, J. F.; Biagas, B. A.; Rhodes, L. V.; Pei, D. T.; Tucker, H. A.; Llamas, C.; Bowles, A. C.; Dutreil, M. F.; Zhang, S.; et al. Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Res. 2015, 17, 112. [CrossRef] [PubMed]
119. Xue, J.; Zhu, Y.; Sun, Z.; Ji, R.; Zhang, X.; Xu, W.; Yuan, X.; Zhang, B.; Yan, Y.; Yin, L.; et al. Tumorigenic hybrids between mesenchymal stem cells and gastric cancer cells enhanced cancer proliferation, migration and stemness. BMC Cancer 2015, 15, 793. [CrossRef] [PubMed]
120. He, X.; Tsang, T. C.; Pipes, B. L.; Ablin, R. J.; Harris, D. T. A stem cell fusion model of carcinogenesis. J. Exp. Ther. Oncol. 2005, 5, 101-109. [PubMed]
121. Rizvi, A. Z.; Swain, J. R.; Davies, P. S.; Bailey, A. S.; Decker, A. D.; Willenbring, H.; Grompe, M.; Fleming, W. H.; Wong, M. H. Bone marrow-derived cells fuse with normal and transformed intestinal stem cells. Proc. Natl. Acad. Sci. USA 2006, 103, 6321-6325. [CrossRef] [PubMed]
122. Schichor, C.; Albrecht, V.; Korte, B.; Buchner, A.; Riesenberg, R.; Mysliwietz, J.; Paron, I.; Motaln, H.; Turnsek, T. L.; Jurchott, K.; et al. Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Exp. Neurol. 2012, 234, 208-219. [CrossRef] [PubMed]
123. Xu, M. H.; Gao, X.; Luo, D.; Zhou, X. D.; Xiong, W.; Liu, G. X. EMT and acquisition of stem cell-like properties are involved in spontaneous formation of tumorigenic hybrids between lung cancer and bone marrow-derived mesenchymal stem cells. PLoS ONE 2014, 9. [CrossRef] [PubMed]
124. Li, H.; Feng, Z.; Tsang, T. C.; Tang, T.; Jia, X.; He, X.; Pennington, M. E.; Badowski, M. S.; Liu, A. K.; Chen, D.; et al. Fusion of HepG2 cells with mesenchymal stem cells increases cancer associated and malignant properties: An in vivo metastasis model. Oncol. Rep. 2014, 32, 539-547. [CrossRef] [PubMed]
125. Ricci-Vitiani, L.; Lombardi, D. G.; Pilozzi, E.; Biffoni, M.; Todaro, M.; Peschle, C.; de Maria, R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445, 111-115. [CrossRef] [PubMed]
126. Kakarala, M.; Wicha, M. S. Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. J. Clin. Oncol. 2008, 26, 2813-2820. [CrossRef] [PubMed]
127. Liu, S.; Ginestier, C.; Ou, S. J.; Clouthier, S. G.; Patel, S. H.; Monville, F.; Korkaya, H.; Heath, A.; Dutcher, J.; Kleer, C. G.; et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res. 2011, 71, 614-624. [CrossRef] [PubMed]
128. McLean, K.; Gong, Y.; Choi, Y.; Deng, N.; Yang, K.; Bai, S.; Cabrera, L.; Keller, E.; McCauley, L.; Cho, K. R.; et al. Human ovarian carcinoma-associated mesenchymal stem cells regulate cancer stem cells and tumorigenesis via altered BMP production. J. Clin. Investig. 2011, 121, 3206-3219. [CrossRef] [PubMed]
129. Tsukamoto, S.; Honoki, K.; Fujii, H.; Tohma, Y.; Kido, A.; Mori, T.; Tsujiuchi, T.; Tanaka, Y. Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Int. J. Oncol. 2012, 40, 163-169. [PubMed]
130. Shinagawa, K.; Kitadai, Y.; Tanaka, M.; Sumida, T.; Kodama, M.; Higashi, Y.; Tanaka, S.; Yasui, W.; Chayama, K. Mesenchymal stem cells enhance growth and metastasis of colon cancer. Int. J. Cancer 2010, 127, 2323-2333. [CrossRef] [PubMed]
131. Yang, X.; Hou, J.; Han, Z.; Wang, Y.; Hao, C.; Wei, L.; Shi, Y. One cell, multiple roles: Contribution of mesenchymal stem cells to tumor development in tumor microenvironment. Cell Biosci. 2013, 3, 5. [CrossRef] [PubMed]
132. Madrigal, M.; Rao, K. S.; Riordan, N. H. A review of therapeutic effects of mesenchymal stem cell secretions and induction of secretory modification by different culture methods. J. Transl. Med. 2014, 12, 260. [CrossRef] [PubMed]
133. Berniakovich, I.; Giorgio, M. Low oxygen tension maintains multipotency, whereas normoxia increases differentiation of mouse bone marrow stromal cells. Int. J. Mol. Sci. 2013, 14, 2119-2134. [CrossRef] [PubMed]
134. Sanchez, C.; Oskowitz, A.; Pochampally, R. R. Epigenetic reprogramming of IGF1 and leptin genes by serum deprivation in multipotential mesenchymal stromal cells. Stem Cells 2009, 27, 375-382. [CrossRef] [PubMed]
135. Hung, S. C.; Pochampally, R. R.; Hsu, S. C.; Sanchez, C.; Chen, S. C.; Spees, J.; Prockop, D. J. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS ONE 2007, 2. [CrossRef] [PubMed]
136. Hung, S. C.; Pochampally, R. R.; Chen, S. C.; Hsu, S. C.; Prockop, D. J. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells 2007, 25, 2363-2370. [CrossRef] [PubMed]
137. Efimenko, A.; Starostina, E.; Kalinina, N.; Stolzing, A. Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning. J. Transl. Med. 2011, 9, 10. [CrossRef] [PubMed]
138. Park, J. B.; Lee, J. S.; Cho, B. P.; Rhee, K. J.; Baik, S. K.; Kim, J.; Kang, S. J.; Park, D. J.; Oh, J. E.; Shin, H. C.; et al. Adipose tissue-derived mesenchymal stem cells cultured at high cell density express brain-derived neurotrophic factor and exert neuroprotective effects in a 6-hydroxydopamine rat model of Parkinson's disease. Genes Genom. 2015, 37, 213-221. [CrossRef]
139. Dias, S.; Choy, M.; Alitalo, K.; Rafii, S. Vascular endothelial growth factor (VEGF)-C signaling through FLT-4 (VEGFR-3) mediates leukemic cell proliferation, survival, and resistance to chemotherapy. Blood 2002, 99, 2179-2184. [CrossRef] [PubMed]
140. Dias, S.; Shmelkov, S. V.; Lam, G.; Rafii, S. VEGF165 promotes survival of leukemic cells by Hsp90-mediated induction of Bcl-2 expression and apoptosis inhibition. Blood 2002, 99, 2532-2540. [CrossRef] [PubMed]
141. Konig, A.; Menzel, T.; Lynen, S.; Wrazel, L.; Rosen, A.; al-Katib, A.; Raveche, E.; Gabrilove, J. L. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997, 11, 258-265. [CrossRef] [PubMed]
142. Brogi, E.; Wu, T.; Namiki, A.; Isner, J. M. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994, 90, 649-652. [CrossRef] [PubMed]
143. Burger, J. A.; Tsukada, N.; Burger, M.; Zvaifler, N. J.; Dell'Aquila, M.; Kipps, T. J. Blood-derived nurse-like cells protect chronic lymphocytic leukemia B cells from spontaneous apoptosis through stromal cell-derived factor-1. Blood 2000, 96, 2655-2663. [PubMed]
144. Ohlsson, L. B.; Varas, L.; Kjellman, C.; Edvardsen, K.; Lindvall, M. Mesenchymal progenitor cell-mediated inhibition of tumor growth in vivo and in vitro in gelatin matrix. Exp. Mol. Pathol. 2003, 75, 248-255. [CrossRef] [PubMed]
145. Lu, Y. R.; Yuan, Y.; Wang, X. J.; Wei, L. L.; Chen, Y. N.; Cong, C.; Li, S. F.; Long, D.; Tan, W. D.; Mao, Y. Q.; et al. The growth inhibitory effect of mesenchymal stem cells on tumor cells in vitro and in vivo. Cancer Biol. Ther. 2008, 7, 245-251. [CrossRef] [PubMed]
146. Ryu, H.; Oh, J. E.; Rhee, K. J.; Baik, S. K.; Kim, J.; Kang, S. J.; Sohn, J. H.; Choi, E.; Shin, H. C.; Kim, Y. M.; et al. Adipose tissue-derived mesenchymal stem cells cultured at high density express IFN-β and suppress the growth of MCF-7 human breast cancer cells. Cancer Lett. 2014, 352, 220-227. [CrossRef] [PubMed]
147. Du, J.; Zhou, L.; Chen, X.; Yan, S.; Ke, M.; Lu, X.; Wang, Z.; Yu, W.; Xiang, A. P. IFN-primed human bone marrow mesenchymal stem cells induce tumor cell apoptosis in vitro via tumor necrosis factor-related apoptosis-inducing ligand. Int. J. Biochem. Cell Biol. 2012, 44, 1305-1314. [CrossRef] [PubMed]
148. Secchiero, P.; Zorzet, S.; Tripodo, C.; Corallini, F.; Melloni, E.; Caruso, L.; Bosco, R.; Ingrao, S.; Zavan, B.; Zauli, G. Human bone marrow mesenchymal stem cells display anti-cancer activity in scid mice bearing disseminated non-Hodgkin's lymphoma xenografts. PLoS ONE 2010, 5. [CrossRef] [PubMed]
149. Glennie, S.; Soeiro, I.; Dyson, P. J.; Lam, E. W.; Dazzi, F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105, 2821-2827. [CrossRef] [PubMed]
150. Aggarwal, S.; Pittenger, M. F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105, 1815-1822. [CrossRef] [PubMed]
151. Corcione, A.; Benvenuto, F.; Ferretti, E.; Giunti, D.; Cappiello, V.; Cazzanti, F.; Risso, M.; Gualandi, F.; Mancardi, G. L.; Pistoia, V.; et al. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107, 367-372. [CrossRef] [PubMed]
152. Sotiropoulou, P. A.; Perez, S. A.; Gritzapis, A. D.; Baxevanis, C. N.; Papamichail, M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006, 24, 74-85. [CrossRef] [PubMed]
153. Ramasamy, R.; Lam, E. W.; Soeiro, I.; Tisato, V.; Bonnet, D.; Dazzi, F. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: Impact on in vivo tumor growth. Leukemia 2007, 21, 304-310. [CrossRef] [PubMed]
154. Engelman, J. A.; Luo, J.; Cantley, L. C. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 2006, 7, 606-619. [CrossRef] [PubMed]
155. Cantley, L. C. The phosphoinositide 3-kinase pathway. Science 2002, 296, 1655-1657. [CrossRef] [PubMed]
156. Altomare, D. A.; Khaled, A. R. Homeostasis and the importance for a balance between AKT/mTOR activity and intracellular signaling. Curr. Med. Chem. 2012, 19, 3748-3762. [CrossRef] [PubMed]
157. Song, M. S.; Salmena, L.; Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13, 283-296. [CrossRef] [PubMed]
158. Jiang, B. H.; Liu, L. Z. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv. Cancer Res. 2009, 102, 19-65. [CrossRef] [PubMed]
159. Croce, J. C.; McClay, D. R. Evolution of the Wnt pathways. Methods Mol. Biol. 2008, 469, 3-18. [PubMed]
160. Polakis, P. Wnt signaling and cancer. Genes Dev. 2000, 14, 1837-1851. [CrossRef] [PubMed]
161. Giles, R. H.; van Es, J. H.; Clevers, H. Caught up in a wnt storm: Wnt signaling in cancer. Biochim. Biophys. Acta 2003, 1653, 1-24. [CrossRef]
162. Logan, C. Y.; Nusse, R. The Wnt signaling pathway in development and disease. Annu. Rev. Cell Dev. Biol. 2004, 20, 781-810. [CrossRef] [PubMed]
163. Boerboom, D.; Paquet, M.; Hsieh, M.; Liu, J.; Jamin, S. P.; Behringer, R. R.; Sirois, J.; Taketo, M. M.; Richards, J. S. Misregulated Wnt/β-catenin signaling leads to ovarian granulosa cell tumor development. Cancer Res. 2005, 65, 9206-9215. [CrossRef] [PubMed]
164. Monga, S. P. β-Catenin signaling and roles in liver homeostasis, injury, and tumorigenesis. Gastroenterology 2015, 148, 1294-1310. [CrossRef] [PubMed]
165. Chiurillo, M. A. Role of the Wnt/β-catenin pathway in gastric cancer: An in-depth literature review. World J. Exp. Med. 2015, 5, 84-102. [CrossRef] [PubMed]
166. Incassati, A.; Chandramouli, A.; Eelkema, R.; Cowin, P. Key signaling nodes in mammary gland development and cancer: β-Catenin. Breast Cancer Res. 2010, 12, 213. [CrossRef] [PubMed]
167. Roarty, K.; Rosen, J. M. Wnt and mammary stem cells: Hormones cannot fly wingless. Curr. Opin. Pharmacol. 2010, 10, 643-649. [CrossRef] [PubMed]
168. King, T. D.; Suto, M. J.; Li, Y. The wnt/β-catenin signaling pathway: A potential therapeutic target in the treatment of triple negative breast cancer. J. Cell. Biochem. 2012, 113, 13-18. [CrossRef] [PubMed]
169. Gaspar, C.; Fodde, R. APC dosage effects in tumorigenesis and stem cell differentiation. Int. J. Dev. Biol. 2004, 48, 377-386. [CrossRef] [PubMed]
170. Chen, G.; Shukeir, N.; Potti, A.; Sircar, K.; Aprikian, A.; Goltzman, D.; Rabbani, S. A. Up-regulation of Wnt-1 and β-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications. Cancer 2004, 101, 1345-1356. [CrossRef] [PubMed]
171. Moon, R. T.; Kohn, A. D.; De Ferrari, G. V.; Kaykas, A. WNT and β-catenin signalling: Diseases and therapies. Nat. Rev. Genet. 2004, 5, 691-701. [CrossRef] [PubMed]
172. Loebinger, M. R.; Eddaoudi, A.; Davies, D.; Janes, S. M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009, 69, 4134-4142. [CrossRef] [PubMed]
173. Nakamizo, A.; Marini, F.; Amano, T.; Khan, A.; Studeny, M.; Gumin, J.; Chen, J.; Hentschel, S.; Vecil, G.; Dembinski, J.; et al. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005, 65, 3307-3318. [PubMed]
174. Menon, L. G.; Picinich, S.; Koneru, R.; Gao, H.; Lin, S. Y.; Koneru, M.; Mayer-Kuckuk, P.; Glod, J.; Banerjee, D. Differential gene expression associated with migration of mesenchymal stem cells to conditioned medium from tumor cells or bone marrow cells. Stem Cells 2007, 25, 520-528. [CrossRef] [PubMed]
175. Xin, H.; Kanehira, M.; Mizuguchi, H.; Hayakawa, T.; Kikuchi, T.; Nukiwa, T.; Saijo, Y. Targeted delivery of CX3CL1 to multiple lung tumors by mesenchymal stem cells. Stem Cells 2007, 25, 1618-1626. [CrossRef] [PubMed]
176. Komarova, S.; Kawakami, Y.; Stoff-Khalili, M. A.; Curiel, D. T.; Pereboeva, L. Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol. Cancer Ther. 2006, 5, 755-766. [CrossRef] [PubMed]
177. Mendes, S. C.; Robin, C.; Dzierzak, E. Mesenchymal progenitor cells localize within hematopoietic sites throughout ontogeny. Development 2005, 132, 1127-1136. [CrossRef] [PubMed]
178. Sordi, V.; Malosio, M. L.; Marchesi, F.; Mercalli, A.; Melzi, R.; Giordano, T.; Belmonte, N.; Ferrari, G.; Leone, B. E.; Bertuzzi, F.; et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. Blood 2005, 106, 419-427. [CrossRef] [PubMed]
179. Giordano, A.; Galderisi, U.; Marino, I. R. From the laboratory bench to the patient's bedside: An update on clinical trials with mesenchymal stem cells. J. Cell. Physiol. 2007, 211, 27-35. [CrossRef] [PubMed]
180. Subramanian, A.; Shu-Uin, G.; Kae-Siang, N.; Gauthaman, K.; Biswas, A.; Choolani, M.; Bongso, A.; Chui-Yee, F. Human umbilical cord Wharton's jelly mesenchymal stem cells do not transform to tumor-associated fibroblasts in the presence of breast and ovarian cancer cells unlike bone marrow mesenchymal stem cells. J. Cell. Biochem. 2012, 113, 1886-1895. [CrossRef] [PubMed]
181. Lotfi, R.; Eisenbacher, J.; Solgi, G.; Fuchs, K.; Yildiz, T.; Nienhaus, C.; Rojewski, M. T.; Schrezenmeier, H. Human mesenchymal stem cells respond to native but not oxidized damage associated molecular pattern molecules from necrotic (tumor) material. Eur. J. Immunol. 2011, 41, 2021-2028. [CrossRef] [PubMed]
182. Barbash, I. M.; Chouraqui, P.; Baron, J.; Feinberg, M. S.; Etzion, S.; Tessone, A.; Miller, L.; Guetta, E.; Zipori, D.; Kedes, L. H.; et al. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: Feasibility, cell migration, and body distribution. Circulation 2003, 108, 863-868. [CrossRef] [PubMed]
183. Nystedt, J.; Anderson, H.; Tikkanen, J.; Pietila, M.; Hirvonen, T.; Takalo, R.; Heiskanen, A.; Satomaa, T.; Natunen, S.; Lehtonen, S.; et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells 2013, 31, 317-326. [CrossRef] [PubMed]
184. Di Bonzo, L. V.; Ferrero, I.; Cravanzola, C.; Mareschi, K.; Rustichell, D.; Novo, E.; Sanavio, F.; Cannito, S.; Zamara, E.; Bertero, M.; et al. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: Engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 2008, 57, 223-231. [CrossRef] [PubMed]
185. Baertschiger, R. M.; Serre-Beinier, V.; Morel, P.; Bosco, D.; Peyrou, M.; Clement, S.; Sgroi, A.; Kaelin, A.; Buhler, L. H.; Gonelle-Gispert, C. Fibrogenic potential of human multipotent mesenchymal stromal cells in injured liver. PLoS ONE 2009, 4. [CrossRef] [PubMed]
186. Janowski, M.; Lyczek, A.; Engels, C.; Xu, J.; Lukomska, B.; Bulte, J. W.; Walczak, P. Cell size and velocity of injection are major determinants of the safety of intracarotid stem cell transplantation. J. Cereb. Blood Flow Metab. 2013, 33, 921-927. [CrossRef] [PubMed]
187. Schrepfer, S.; Deuse, T.; Reichenspurner, H.; Fischbein, M. P.; Robbins, R. C.; Pelletier, M. P. Stem cell transplantation: The lung barrier. Transplant. Proc. 2007, 39, 573-576. [CrossRef] [PubMed]
188. Studeny, M.; Marini, F. C.; Champlin, R. E.; Zompetta, C.; Fidler, I. J.; Andreeff, M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002, 62, 3603-3608. [PubMed]
189. Ren, C.; Kumar, S.; Chanda, D.; Chen, J.; Mountz, J. D.; Ponnazhagan, S. Therapeutic potential of mesenchymal stem cells producing interferon-α in a mouse melanoma lung metastasis model. Stem Cells 2008, 26, 2332-2338. [CrossRef] [PubMed]
190. Ren, C.; Kumar, S.; Chanda, D.; Kallman, L.; Chen, J.; Mountz, J. D.; Ponnazhagan, S. Cancer gene therapy using mesenchymal stem cells expressing interferon-β in a mouse prostate cancer lung metastasis model. Gene Ther. 2008, 15, 1446-1453. [CrossRef] [PubMed]
191. Chen, X. C.; Wang, R.; Zhao, X.; Wei, Y. Q.; Hu, M.; Wang, Y. S.; Zhang, X. W.; Zhang, R.; Zhang, L.; Yao, B.; et al. Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis 2006, 27, 2434-2441. [CrossRef] [PubMed]
192. Nakamura, K.; Ito, Y.; Kawano, Y.; Kurozumi, K.; Kobune, M.; Tsuda, H.; Bizen, A.; Honmou, O.; Niitsu, Y.; Hamada, H. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004, 11, 1155-1164. [CrossRef] [PubMed]
193. Chen, X.; Lin, X.; Zhao, J.; Shi, W.; Zhang, H.; Wang, Y.; Kan, B.; Du, L.; Wang, B.; Wei, Y.; et al. A tumor-selective biotherapy with prolonged impact on established metastases based on cytokine gene-engineered MSCs. Mol. Ther. 2008, 16, 749-756. [CrossRef] [PubMed]
194. Kidd, S.; Caldwell, L.; Dietrich, M.; Samudio, I.; Spaeth, E. L.; Watson, K.; Shi, Y.; Abbruzzese, J.; Konopleva, M.; Andreeff, M.; et al. Mesenchymal stromal cells alone or expressing interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory treatment. Cytotherapy 2010, 12, 615-625. [CrossRef] [PubMed]
195. Gao, P.; Ding, Q.; Wu, Z.; Jiang, H.; Fang, Z. Therapeutic potential of human mesenchymal stem cells producing IL-12 in a mouse xenograft model of renal cell carcinoma. Cancer Lett. 2010, 290, 157-166. [CrossRef] [PubMed]
196. Hakkarainen, T.; Sarkioja, M.; Lehenkari, P.; Miettinen, S.; Ylikomi, T.; Suuronen, R.; Desmond, R. A.; Kanerva, A.; Hemminki, A. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors. Hum. Gene Ther. 2007, 18, 627-641. [CrossRef] [PubMed]
197. Stoff-Khalili, M. A.; Rivera, A. A.; Mathis, J. M.; Banerjee, N. S.; Moon, A. S.; Hess, A.; Rocconi, R. P.; Numnum, T. M.; Everts, M.; Chow, L. T.; et al. Mesenchymal stem cells as a vehicle for targeted delivery of crads to lung metastases of breast carcinoma. Breast Cancer Res. Treat. 2007, 105, 157-167. [CrossRef] [PubMed]
198. Kucerova, L.; Matuskova, M.; Pastorakova, A.; Tyciakova, S.; Jakubikova, J.; Bohovic, R.; Altanerova, V.; Altaner, C. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J. Gene Med. 2008, 10, 1071-1082. [CrossRef] [PubMed]
199. Kucerova, L.; Altanerova, V.; Matuskova, M.; Tyciakova, S.; Altaner, C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007, 67, 6304-6313. [CrossRef] [PubMed]
200. Li, L.; Guan, Y.; Liu, H.; Hao, N.; Liu, T.; Meng, X.; Fu, C.; Li, Y.; Qu, Q.; Zhang, Y.; et al. Silica nanorattle-doxorubicin-anchored mesenchymal stem cells for tumor-tropic therapy. ACS Nano 2011, 5, 7462-7470. [CrossRef] [PubMed]
201. Xiang, H.; Nguyen, C. B.; Kelley, S. K.; Dybdal, N.; Escandon, E. Tissue distribution, stability, and pharmacokinetics of APO2 ligand/tumor necrosis factor-related apoptosis-inducing ligand in human colon carcinoma COLO205 tumor-bearing nude mice. Drug Metab. Dispos. 2004, 32, 1230-1238. [CrossRef] [PubMed]
202. Menon, L. G.; Kelly, K.; Yang, H. W.; Kim, S. K.; Black, P. M.; Carroll, R. S. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009, 27, 2320-2330. [CrossRef] [PubMed]
203. Stagg, J.; Lejeune, L.; Paquin, A.; Galipeau, J. Marrow stromal cells for interleukin-2 delivery in cancer immunotherapy. Hum. Gene Ther. 2004, 15, 597-608. [CrossRef] [PubMed]
204. Eliopoulos, N.; Francois, M.; Boivin, M. N.; Martineau, D.; Galipeau, J. Neo-organoid of marrow mesenchymal stromal cells secreting interleukin-12 for breast cancer therapy. Cancer Res. 2008, 68, 4810-4818. [CrossRef] [PubMed]
205. Dembinski, J. L.; Spaeth, E. L.; Fueyo, J.; Gomez-Manzano, C.; Studeny, M.; Andreeff, M.; Marini, F. C. Reduction of nontarget infection and systemic toxicity by targeted delivery of conditionally replicating viruses transported in mesenchymal stem cells. Cancer Gene Ther. 2010, 17, 289-297. [CrossRef] [PubMed]
206. Uchibori, R.; Okada, T.; Ito, T.; Urabe, M.; Mizukami, H.; Kume, A.; Ozawa, K. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J. Gene Med. 2009, 11, 373-381. [CrossRef] [PubMed]
207. Matuskova, M.; Hlubinova, K.; Pastorakova, A.; Hunakova, L.; Altanerova, V.; Altaner, C.; Kucerova, L. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett. 2010, 290, 58-67. [CrossRef] [PubMed]
208. Zischek, C.; Niess, H.; Ischenko, I.; Conrad, C.; Huss, R.; Jauch, K. W.; Nelson, P. J.; Bruns, C. Targeting tumor stroma using engineered mesenchymal stem cells reduces the growth of pancreatic carcinoma. Ann. Surg. 2009, 250, 747-753. [CrossRef] [PubMed]
209. Hamada, H.; Kobune, M.; Nakamura, K.; Kawano, Y.; Kato, K.; Honmou, O.; Houkin, K.; Matsunaga, T.; Niitsu, Y. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci. 2005, 96, 149-156. [CrossRef] [PubMed]
210. Kim, G.; Eom, Y. W.; Baik, S. K.; Shin, Y.; Lim, Y. L.; Kim, M. Y.; Kwon, S. O.; Chang, S. J. Therapeutic effects of mesenchymal stem cells for patients with chronic liver diseases: Systematic review and meta-analysis. J. Korean Med. Sci. 2015, 30, 1405-1415. [CrossRef] [PubMed]